Xenon Pharmaceuticals (XENE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Ion Channel CNSsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 24/100 (LOW), 49.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.66% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
- Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
- Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
- Ian Mortimer Receives the 2026 Bloom Burton Award
- Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
- Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Five-year Quantitative Chest CT and Hyperpolarized Xenon 129 Ventilation MRI Findings in Survivors of COVID-19 Pneumonia. — Radiology 2026 Sep PMID 42770821
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Xenon Pharmaceuticals.
Full XENE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.